Literature DB >> 17187395

Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.

Samar Hamdy1, Praveen Elamanchili, Aws Alshamsan, Ommoleila Molavi, Tadaaki Satou, John Samuel.   

Abstract

The purpose of this research was to investigate the use of biodegradable poly(D,L-lactic-co-glycolic acid) nanoparticles (PLGA-NP) as a vaccine delivery system to codeliver antigen, ovalbumin (OVA) along with monophosphoryl lipid A (MPLA) as adjuvant for induction of potent CD4(+) and CD8(+) T cell responses. The primary CD4(+) T responses to OVA/MPLA NP were investigated using OVA-specific T cells from DO11.10 transgenic mice. Following adoptive transfer of these cells, mice were immunized s.c. by NP formulations. For assessing the CD8(+) responses, bone marrow derived dendritic cells (DCs) were pulsed with different OVA formulations, then, cocultured with CD8(+) T cells from OT-1 mice. T cell proliferation/activation and IFN-gamma secretion profile have been examined. Particulate delivery of OVA and MPLA to the DCs lead to markedly increase in in vitro CD8(+) T cell T cell proliferative responses (stimulation index >3000) and >13-folds increase in in vivo clonal expanded CD4(+) T cells. The expanded T cells were capable of cytokine secretion and expressed an activation and memory surface phenotype (CD62L(lo), CD11a(hi), and CD44(hi)). Codelivery of antigen and MPLA in PLGA-NP offers an effective method for induction of potent antigen specific CD4(+) and CD8(+) T cell responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187395     DOI: 10.1002/jbm.a.31019

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  34 in total

1.  Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.

Authors:  Wen-Hui Luo; Ya-Wun Yang
Journal:  Pharm Res       Date:  2015-12-29       Impact factor: 4.200

Review 2.  Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles.

Authors:  Esmaiel Jabbari
Journal:  Pharm Res       Date:  2008-12-17       Impact factor: 4.200

3.  Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

Authors:  Heng Liu; Jacqueline de Vries-Idema; Wouter Ter Veer; Jan Wilschut; Anke Huckriede
Journal:  Med Microbiol Immunol       Date:  2013-09-24       Impact factor: 3.402

4.  Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy.

Authors:  Suzanne Foster; Craig L Duvall; Emily F Crownover; Allan S Hoffman; Patrick S Stayton
Journal:  Bioconjug Chem       Date:  2010-11-02       Impact factor: 4.774

5.  Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles.

Authors:  Samar Hamdy; Azita Haddadi; Anooshirvan Shayeganpour; John Samuel; Afsaneh Lavasanifar
Journal:  Pharm Res       Date:  2011-05-11       Impact factor: 4.200

Review 6.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

7.  Cross-Platform Comparison of Therapeutic Delivery from Multilamellar Lipid-Coated Polymer Nanoparticles.

Authors:  Sharon Golan-Paz; Hannah Frizzell; Kim A Woodrow
Journal:  Macromol Biosci       Date:  2018-12-27       Impact factor: 4.979

Review 8.  Clustered carbohydrates in synthetic vaccines.

Authors:  Francesco Peri
Journal:  Chem Soc Rev       Date:  2012-12-18       Impact factor: 54.564

9.  The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.

Authors:  Yun Hu; Daniel Smith; Evan Frazier; Reece Hoerle; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2016-08-18       Impact factor: 12.479

10.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.